Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

292
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
292
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

822
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
822
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

757
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
757
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.2K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.0K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

862
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
862

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human induced pluripotent stem cell-derived cardiomyocyte patch enhances cardiac regeneration in a J2N-k hamster model of dilated cardiomyopathy.

Regenerative therapyยท2026
Same author

Impact of Diabetes on the Efficacy of Low-Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS-AF Trial.

Journal of the American Heart Associationยท2026
Same author

The tube-plugging test: a simple assay that reveals offspring-centered defensive behavior in postpartum mice.

Frontiers in behavioral neuroscienceยท2026
Same author

Efficacy of Low-Voltage Area Ablation Across Substrate Size in Persistent Atrial Fibrillation: A Post Hoc Analysis of the SUPPRESS-AF Randomized Trial.

Journal of the American Heart Associationยท2026
Same author

Complete Low-Voltage Area Ablation in Persistent Atrial Fibrillationใ€€- Post Hoc Subanalysis of the SUPPRESS-AF Trial.

Circulation journal : official journal of the Japanese Circulation Societyยท2026
Same author

A Novel Guidewire Bias Modification Method for Atherectomy of Severely Calcified Femoropopliteal Lesion: JET BIAS.

JACC. Case reportsยท2026

Related Experiment Video

Updated: Jan 26, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

[Ischemic heart failure].

Koichi Inoue1, Masatsugu Hori

  • 1Department of Internal Medicine and Therapeutics, Osaka University, Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 21, 2003
PubMed
Summary

Ischemic heart failure, a common cause of left ventricular dysfunction, may benefit from ACE inhibitors and beta-blockers. Further research is needed for coronary-focused treatments like revascularization.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Myocardial Ischemia

Context:

  • Ischemic heart failure is a primary cause of left ventricular systolic dysfunction.
  • Current understanding suggests two therapeutic strategies: slowing disease progression and preventing myocardial ischemia.
  • Existing treatments like ACE inhibitors and beta-blockers show promise in improving outcomes.

Purpose:

  • To review current treatment strategies for ischemic heart failure.
  • To evaluate the efficacy and safety of various therapeutic approaches.
  • To highlight ongoing clinical trials for coronary syndrome treatments.

Summary:

  • Angiotensin converting enzyme (ACE) inhibitors and beta-blockers enhance left ventricular function and prevent coronary events in ischemic heart failure patients.

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K

Related Experiment Videos

Last Updated: Jan 26, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K
  • Spironolactone may also offer prognostic benefits.
  • Treatments targeting coronary arteries, including antithrombotic agents and revascularization, lack proven efficacy and safety in this patient group.

    • Impact:

    • Provides a concise overview of current and investigational treatments for ischemic heart failure.
    • Identifies gaps in knowledge regarding the effectiveness of coronary-focused therapies.
    • Emphasizes the importance of ongoing large-scale clinical trials to guide future management.